Clinical Trial
doi: 10.1002/mds.20235.
Effects of rivastigmine on motor and cognitive impairment in Huntington's disease
Affiliations
- PMID: 15390067
- DOI: 10.1002/mds.20235
Item in Clipboard
Clinical Trial
Effects of rivastigmine on motor and cognitive impairment in Huntington's disease
Mov Disord.
2004 Dec.
Abstract
To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington's disease (HD), we carried out a prospective, open-label, randomized, controlled study. Twenty-one HD patients were enrolled: 14 were randomly sorted into medication and 7 to no-treatment groups. Clinical and demographic features were similar between groups. After 8 months, an efficacy evaluation was carried out to compare the two groups. The improvement of cholinergic transmission in HD patients seemed to have a slight effect in ameliorating cognitive performance and slowing motor deterioration.
2004 Movement Disorder Society.
Similar articles
-
Two years' follow-up of rivastigmine treatment in Huntington disease.Clin Neuropharmacol. 2007 Jan-Feb;30(1):43-6. doi: 10.1097/01.wnf.0000240945.44370.f0. Clin Neuropharmacol. 2007. PMID: 17272969 Clinical Trial.
-
[Huntington chorea. Clinical correlations and preliminary neuropsychological data].Acta Neurol (Napoli). 1992 Aug-Dec;14(4-6):530-6. Acta Neurol (Napoli). 1992. PMID: 1293994 Italian.
-
Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.Curr Med Res Opin. 2004 Oct;20(10):1605-12. doi: 10.1185/030079904125004204. Curr Med Res Opin. 2004. PMID: 15462693 Clinical Trial.
-
Pharmacologic approaches to the treatment of Huntington's disease.Mov Disord. 2012 Jan;27(1):31-41. doi: 10.1002/mds.23953. Epub 2011 Oct 13. Mov Disord. 2012. PMID: 21997232 Review.
-
[Neuropsychological evaluation can contribute to the diagnosis of movement disorders].Rev Neurol (Paris). 2003 May;159(5 Pt 2):3S50-6. Rev Neurol (Paris). 2003. PMID: 12773888 Review. French.
Cited by
-
Varenicline improves motor and cognitive symptoms in early Huntington's disease.Neuropsychiatr Dis Treat. 2016 Sep 19;12:2381-2386. doi: 10.2147/NDT.S111083. eCollection 2016. Neuropsychiatr Dis Treat. 2016. PMID: 27695336 Free PMC article.
-
Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats.Neuropharmacology. 2007 Feb;52(2):542-51. doi: 10.1016/j.neuropharm.2006.08.025. Epub 2006 Oct 12. Neuropharmacology. 2007. PMID: 17046031 Free PMC article.
-
Huntington's Disease.Curr Treat Options Neurol. 2006 May;8(3):236-44. doi: 10.1007/s11940-006-0014-x. Curr Treat Options Neurol. 2006. PMID: 16569382
-
Symptomatic treatment of Huntington disease.Neurotherapeutics. 2008 Apr;5(2):181-97. doi: 10.1016/j.nurt.2008.01.008. Neurotherapeutics. 2008. PMID: 18394562 Free PMC article. Review.
-
Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review.World J Psychiatry. 2013 Sep 22;3(3):62-4. doi: 10.5498/wjp.v3.i3.62. World J Psychiatry. 2013. PMID: 24255877 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
